Biovica has recently signed its first two US Hospital chain contracts.

Redeye Research just published an interview with Biovica's CEO, Anders Rylander, and President of Americas, Warren Cressel, regarding this achievement.

https://www.redeye.se/research/944123/biovica-interview-with-ceo-anders-rylander-and-warren-cressel-president-americas?utm_medium=email

Biovica is presenting tomorrow at RedEye Research conference. It is free.


Registration:
https://www.redeye.se/events/904816/redeye-theme-medtech-diagnostics-2?utm_source=MB&utm_medium=email&tab=schedule

Biovica is presenting today at the Redeye Research conference. You can join using below link:

https://www.redeye.se/events/904816/redeye-theme-medtech-diagnostics-2?utm_source=MB&utm_medium=email

Redeye Research explains the importance of Biovica's Medicare achievement announced yesterday:

https://www.redeye.se/research/944877/biovica-cms-has-issued-a-preliminary-clinical-laboratory-fee-schedule-clfs-payment-decision-for-divitum-tka-to-pursue-the-gap-fill-process-during-2024?utm_source=MB&utm_medium=email

Today Redeye research on Biovica - it is free with registration

Biovica: Expanding DiviTum’s Nordic market reach

RESEARCH NOTE

2023-11-13

12:33

Biovica has established a partnership agreement with Axlab (A/S) to commercialize the DiviTum in the Nordics. Axlab is especially strong in Denmark and Norway, and the business includes Sweden, Finland and Iceland. Axlab is a top-5 brand in cancer screening and diagnostics in the Nordics. DiviTum will be supported by both Biovica and Axlab in Sweden, and we expect some of the larger centres to represent most of the commercial and clinical activity in Sweden and Denmark over the next 6-18 months. Axlab will showcase DiviTum in their channels and we also expect Axlab to expand the sales team with specialists working with DiviTum. We look forward to a more detailed DiviTum launch update during Biovica’s quarterly result (Q2 2023/24) on 28 November. We are especially interested in the process of approaching commercial DiviTum test volumes from the expanding US Direct Bill network.

https://www.redeye.se/research/958975/biovica-expanding-divitums-nordic-market-reach?utm_source=notification&utm_medium=email&notificationId=9b676ac0-2f01-4462-8808-f7cec14c1d26

Biovica again delivering

Biovica receives final pricing decision for DiviTum TKa test by Medicare effective 1st January 2024!
"This is great news for Biovica! Being able to Crosswalk saves valuable time in establishing reimbursement and has substantial advantages for both patients and healthcare providers. An established DiviTum TKa price with CMS marks a significant achievement in our reimbursement strategy, considering Medicare patients constitute about half of the total available market for DiviTum TKa. It provides pricing and payment certainty aligned with our previously communicated price levels," said Warren Cresswell, President of Biovica Americas.
Read More: https://loom.ly/LlVRHIU
#biovicb #investors #nasdaqfirstnorth #biomarker

Pareto on Biovica:

Biovica finalized Medicare reimbursement pricing.

Pareto: "As a result, this “crosswalk” reimbursement decision accelerates Biovica’s Medicare reimbursement strategy, ensuring reimbursement of USD 322/test from 1 January 2024 for Medicare-insured patients. The company believes that the average price per test will be around USD 400 as private payers have agreed to significantly higher prices..."

Biovica is delivering on all fronts:

Biovica got Medicare reimbursement
Biovica got reimbursement pricing from Medicare much faster than anybody expected
Biovica has several private reimbursement insurers' contract
Biovica has signed up the first three US hospital chains
Biocica has signed up a partner for Scandinavia

Redeye Research on Biovica´s Medicare positive decision:

https://www.redeye.se/research/962018/biovica-the-medicare-price-is-set-at-usd-322-already-from-1-january-2024?utm_source=notification&utm_medium=email&notificationId=3f479f4c-888c-4974-a057-2c2c2287ac1b

Biovica is presenting tomorrow at Redeye Research conference. Anybody can attend - it is free for all

Biovica FB post today:
Get your invitation! Watch us amongst 40+ Nordic companies at Red Eye Life Science Day, a live-streamed event where investors, businesses, and experts co-create the industry’s future.
Don't miss your opportunity to pose questions directly to our CEO, Anders Rylander, during the 20-minute Q&A session. On Wednesday, 23rd November, at 11 AM CET sharp::
Sign up for a personal invitation here: https://loom.ly/ahL1XVY
Read more here: https://loom.ly/ADFKOcg

Biovica is reporting on Tue:

Register for our Q2 Earnings call taking place:
Tuesday 28th November, 2023 at 15:00 CET.
Click here to register: https://loom.ly/LSSK3f0

Presenters are:
Anders Rylander, CEO
Warren Cresswell, President of Americas
Henrik Winther, SVP Business Development
Anders Morén, CFO

Recording of Biovica´s CEO update from last week Redeye Research conference. It is free

https://www.redeye.se/video/event-presentation/963538/biovica-ceo-anders-rylander-presenterar-pa-redeye-life-science-day-2023-23-november?utm_source=video&utm_medium=email

CEO Anders Rylander presents at STORA AKTIEDAGARNA on Monday 27th November

See the recording from 27th November, where Aktiespararna brought together around 50 small and large Nordic companies for three packed days of investors presentations.

https://youtu.be/rBs2rP3waV0?si=T6q-gN3HlZBDQbSs

Biovica Quarterly report published today:

https://storage.mfn.se/32133ade-abc0-4a8f-b759-f0ee75b1f831/q2-2023-2024-biovica-eng.pdf

Biovica CEO on latest capital raise:

"With great optimism for the future, I will myself be subscribing for SEK 10 million in shares. "

CEO of Biovica:

- I have invested 10 Mil NOK in the capital raise
- our US team invested most of their bonuses into the capital raise. This is a great sign of confidence

Interview with Biovica CEO published today

Biovica's CEO: "DiviTum TKa has had a good start in the US"

https://www.biostock.se/2023/11/biovicas-vd-divitum-tka-har-fatt-en-bra-start-i-usa/

Redeye interview with Biovica management

https://www.redeye.se/research/964847/biovica-interview-with-top-management?utm_source=interview&utm_medium=email

Very good interview - the CEO describes how Biovica is changing how breast cancer is treated

https://www.redeye.se/research/964847/biovica-interview-with-top-management?utm_source=interview&utm_medium=email

Biovica receives license for Maryland state
Biovica, active in cancer diagnostics, today announces that the company has received a license for Maryland state, the 18th largest state in the US. The license means that Biovica can now perform analysis and report patient samples from all US states, except for New York and Washington DC.

"Our reach in the United States is steadily growing. We are now equipped to receive, test and report patient test results in 49 states, encompassing 94% or 311 million U.S. residents. Our latest state license enables us to partner with prominent medical facilities in Maryland, offering DiviTum TKa to oncologists for monitoring metastatic breast cancer in patients," says Warren Cresswell, President of Biovica Americas.

Biovica International AB

Watch the BioStock investor pitch recorded live with CEO, Anders Rylander (in Swedish) at 10:00 AM, December 1.
Click here: https://loom.ly/ADFKOcg

See the latest video interview in Swedish!

Biovica is in full swing with the launch of its cancer test DiviTum TKa to better and faster predict and monitor treatment effect. After several agreements in Europe and the US, Biovica aims for a rights issue of units to finance continued marketing efforts. BioStock has spoken to CEO Anders Rylander to get his thoughts on the launch and the rights issue.

Watch the video interview here: https://loom.ly/ADFKOcg

Question:
What is US doctors take on Biovica’s breast cancer test?


ChatGPT
US doctors and oncologists have shown positive reception towards Biovica's DiviTum® TKa breast cancer test. According to information from Biovica's website, medical professionals like Dr. Cynthia Ma from Washington University and Dr. Luca Malorni from Prato Hospital, Italy, have highlighted the potential of the DiviTum® TKa test in evaluating treatment efficacy early during therapy and monitoring disease progression. They note its capability to identify progression months ahead of imaging [oai_citation:1,
What Oncologists Say - Biovica International AB ](https://biovica.com/about-us/what-oncologists-say/).

The test's utility was further demonstrated in clinical studies like the BioItaLEE trial, which showed that DiviTum® TKa could predict patients' responses to CDK4/6 treatment in cases of hormone receptor-positive, HER-2 negative advanced breast cancer. This trial concluded that testing patient blood samples for both TKa and ctDNA at specific intervals was prognostic for progression-free survival and predictive for treatment response [oai_citation:2,DiviTum®TKa Predicts Clinical Outcome of Patients in BioItaLEE Study | BioSpace](https://www.biospace.com/article/releases/divitum-tka-predicts-clinical-outcome-of-patients-in-bioitalee-study/).

Biovica has also received positive decisions from the Center for Medicare & Medicaid Services, which agreed to crosswalk DiviTum TKa to reimbursement code 0058U, effective from January 1st, 2024. This decision allows for the established pricing and payment certainty of the test, which is significant considering that Medicare patients constitute about half of the total available market for DiviTum TKa [oai_citation:3,Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare Effective 1st January 2024 | BioSpace](https://www.biospace.com/article/releases/biovica-receives-final-pricing-decision-for-divitum-tka-test-by-medicare-effective-1st-january-2024/).

In summary, the response from US doctors towards Biovica’s breast cancer test seems to be encouraging, with clinical studies supporting its efficacy and significant steps being taken towards its integration into healthcare reimbursement systems.

Biovica call with the management. So good

https://www.redeye.se/research/964847/biovica-interview-with-top-management

Pareto:

Biovica today announced that it has signed a distribution agreement with Palex Group, a distributor in Spain and Portugal with a reach to approximately >8000 DiviTum relevant patients per year. Conclusively, this presents an approximate market opportunity of USD 5-8m/year for Biovica – depending on the exact deal terms (unknown) and product uptake.